Methods for monitoring tumors can be invasive and ineffective
Current tumor monitoring methods is their reliance on invasive biopsies, often failing to provide continuous, real-time data on tumor activity and therapeutic response. Existing liquid biopsies also suffer from low sensitivity due to the dilution of biomarkers in blood.
This new invention addresses these issues by utilizing activatable biosensors injected directly into tumors. These biosensors capture dynamic biological activity and immune responses, reporting specific protease activity through detectable molecules in bodily fluids like urine and blood. This method offers non-invasive, highly sensitive monitoring of tumor environments and treatment effectiveness, providing continuous, real-time insights into tumor behavior.
Activatable biosensors capture dynamic biological activity
Utilizing activatable biosensors injected directly into tumors, this invention captures dynamic biological activity and immune responses within solid tumors. These biosensors, designed to report on specific protease activity, allow for the non-invasive monitoring of tumor responses to therapies through the detection of reporter molecules in bodily fluids such as urine and blood. This method offers a less invasive alternative to traditional biopsies, providing real-time insights into tumor behavior and the effectiveness of treatments.
- Non-invasive monitoring
- Improved detection limits over current technologies.
- Enhanced sensitivity and specificity for tumor-specific biomarkers.
- Monitor dynamic changes in the tumor microenvironment over time.
• Drug response monitoring in cancer treatments, particularly for immunotherapies.
• Therapeutic response monitoring across multiple immune cell types within tumor microenvironments.
• Potential for early detection and monitoring of cancer progression through non-invasive means.